Medtronic Percept Neurostimulator for Tourette Syndrome

Phase-Based Progress Estimates
Norman Fixel Institute for Neurological Diseases - University of Florida, Gainesville, FL
Tourette Syndrome+1 More
Medtronic Percept Neurostimulator - Device
All Sexes
What conditions do you have?

Study Summary

The investigators will implant and monitor 8 research subjects with a subcortical closed-loop system for detection and suppression of tics. The project will use the FDA-approved "Medtronic Percept PC" device, which is an implantable neurostimulator capable of recording neural signals. The study will target the CM nucleus of the thalamus and the aGPi in each brain hemisphere from each subject and we will connect the two leads placed in each brain hemisphere to two Percept devices.

Eligible Conditions

  • Tourette Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Tourette Syndrome

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 6 months

6 months
Yale Global Tic Severity Scale_(YGTSS) - Total Tic Score

Trial Safety

Safety Progress

1 of 3

Other trials for Tourette Syndrome

Trial Design

1 Treatment Group

Medtronic Percept Neurostimulator
1 of 1
Experimental Treatment

8 Total Participants · 1 Treatment Group

Primary Treatment: Medtronic Percept Neurostimulator · No Placebo Group · N/A

Medtronic Percept Neurostimulator
Experimental Group · 1 Intervention: Medtronic Percept Neurostimulator · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Norman Fixel Institute for Neurological Diseases - University of Florida · Gainesville, FL
Photo of Gainesville  1Photo of Gainesville  2
N/AFirst Recorded Clinical Trial
1 TrialsResearching Tourette Syndrome
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Subjects will be given botulinum toxin injections to see if they have focal or addressable tics
You must be willing to keep your current treatment stable and unchanged throughout the trial.
You must be at least 18 years of age to participate in this study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.